Skip to main content
SpringerLink
Log in

Diffuse Large B-Cell Lymphoma

  • Chapter
  • First Online:
Lymphoma

Part of the book series: Current Clinical Oncology ((CCO,volume 43))

  • 2612 Accesses

Abstract

The World Health Organization (WHO) classification defines diffuse large B-cell lymphoma (DLBCL) as a group of proliferations of large B-cell lymphoid cells with a diffuse growth pattern. It contains some specific entities and a large group of heterogeneous “not otherwise specified” diseases comprising morphologic variants and immunohistochemical, genetic, and molecular subgroups. DLBCL is the most common hematopoietic malignancy, accounting for one-third of mature B-cell neoplasms. Major advances have been observed in the knowledge and the management of DLBCL in the recent years. If the International Prognosis Index (IPI) is still the primary clinical tool used to predict outcome for patients with DLBCL and to guide therapeutic strategies, gene expression profiling and its related biomarkers delineate at least two major histologically indistinguishable molecular subtypes, the germinal center B-cell-like (GCB) subtype and the activated B-cell-like (ABC) subtype, that differ in cure rates and in responsiveness to targeted therapies, independently of the clinical variables. Functional imaging with fluorine-18 deoxyglucose (FDG) positron emission tomography (PET) has become an indispensable mean of assessing the extent of the disease and treatment response. The advent of rituximab has opened the era of targeted therapies in DLBCL and has markedly modified, in combination with chemotherapy, the outcomes in all DLBCL subgroups.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stein H, Chan JKC, Warnke RA, et al. Diffuse large B-cell lymphoma not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 233–7.

    Google Scholar 

  2. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107:265–76.

    Article  PubMed  CAS  Google Scholar 

  3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  4. d’Amore F, Brincker H, Christensen BE, et al. Non-Hodgkin’s lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. Ann Oncol. 1992;3:379–86.

    PubMed  Google Scholar 

  5. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

    Article  PubMed  CAS  Google Scholar 

  6. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.

    Article  PubMed  CAS  Google Scholar 

  7. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol (Off J Am Soc Clin Oncol). 2007;25:579–86.

    Article  Google Scholar 

  8. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.

    Article  PubMed  CAS  Google Scholar 

  9. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–47.

    Article  PubMed  Google Scholar 

  10. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68–74.

    Article  PubMed  CAS  Google Scholar 

  11. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313–23.

    Article  PubMed  CAS  Google Scholar 

  12. Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin’s lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol. 1990;8:1163–72.

    PubMed  CAS  Google Scholar 

  13. Chung R, Lai R, Wei P, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood. 2007;110:1278–82.

    Article  PubMed  CAS  Google Scholar 

  14. de Kerviler E, de Bazelaire C, Mounier N, et al. Image-guided core-needle biopsy of peripheral lymph nodes allows the diagnosis of lymphomas. Eur Radiol. 2007;17:843–9.

    Article  PubMed  Google Scholar 

  15. Arber DA, George TI. Bone marrow biopsy involvement by non-Hodgkin’s lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol. 2005;29:1549–57.

    Article  PubMed  Google Scholar 

  16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol (Off J Am Soc Clin Oncol). 1999;17:1244.

    CAS  Google Scholar 

  17. Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d’Etudes des Lymphomes de l’Adulte. Ann Oncol. 2000;11:685–90.

    Article  PubMed  CAS  Google Scholar 

  18. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol (Off J Eur Soc Medl Oncol/ESMO). 2004;15:129–33.

    Article  CAS  Google Scholar 

  19. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113:3896–902.

    Article  PubMed  CAS  Google Scholar 

  20. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21:1046–52.

    Article  PubMed  CAS  Google Scholar 

  21. Chihara D, Oki Y, Matsuo K, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma. 2011;52(12):2270–5.

    Article  PubMed  CAS  Google Scholar 

  22. Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105:496–502.

    Article  PubMed  CAS  Google Scholar 

  23. Quijano S, Lopez A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin’s lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009;27:1462–9.

    Article  PubMed  CAS  Google Scholar 

  24. Sancho JM, Orfao A, Quijano S, et al. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin’s lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol. 2010;85:321–8.

    Article  PubMed  CAS  Google Scholar 

  25. Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin’s lymphomas. Cancer Treat Rep. 1977;61:1023–7.

    PubMed  CAS  Google Scholar 

  26. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol (Off J Am Soc Clin Oncol). 2011;29:1844–54.

    Article  Google Scholar 

  27. Ouvrier MJ, Diologent B, Edet-Sanson A, et al. Influence of PET/CT on radiologists and contrast-enhanced CT on nuclear medicine physicians in patients with lymphoma. Q J Nucl Med Mol Imaging. 2011;55:324–33.

    PubMed  CAS  Google Scholar 

  28. Chen YK, Yeh CL, Tsui CC, Liang JA, Chen JH, Kao CH. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-­analysis. Clin Nucl Med. 2011;36:553–9.

    Article  PubMed  CAS  Google Scholar 

  29. Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol (Off J Am Soc Clin Oncol). 2011;29:1452–7.

    Article  Google Scholar 

  30. Herrmann K, Buck AK, Schuster T, et al. Predictive value of initial 18F-FLT uptake in patients with aggres­sive non-Hodgkin lymphoma ­receiving R-CHOP treatment. J Nucl Med (Off Publ Soc Nucl Med). 2011;52:690–6.

    Article  Google Scholar 

  31. Lanic H, Mareschal S, Mechken F, et al. Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;53(1):34–42.

    Article  PubMed  CAS  Google Scholar 

  32. Phan J, Mazloom A, Jeffrey Medeiros L, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol (Off J Am Soc Clin Oncol). 2010;28:4170–6.

    Article  Google Scholar 

  33. Chihara D, Oki Y, Onoda H, et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol. 2011;93:502–8.

    Article  PubMed  Google Scholar 

  34. Meignan M, Itti E, Gallamini A, Haioun C. Interim 18 F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation—where do we stand? Leuk Lymphoma. 2009;50:1753–6.

    Article  PubMed  Google Scholar 

  35. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med (Off Publ Soc Nucl Med). 2007;48:1626–32.

    Article  Google Scholar 

  36. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early ­prognostic tool for predicting patient outcome. Blood. 2005;106:1376–81.

    Article  PubMed  CAS  Google Scholar 

  37. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol (Off J Eur Soc Med Oncol/ESMO). 2002;13:1356–63.

    Article  CAS  Google Scholar 

  38. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50:1257–60.

    Article  PubMed  Google Scholar 

  39. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118(1):37–43.

    Article  PubMed  CAS  Google Scholar 

  40. Safar V, Dupuis J, Itti E, Jardin F, Fruchart C, Bardet S, Véra P, Copie-Bergman C, Rahmouni A, Tilly H, Meignan M, Haioun C. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based ­chemotherapy plus rituximab. J Clin Oncol. 2012;30:184–90.

    Article  PubMed  CAS  Google Scholar 

  41. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003;102:53–9.

    Article  PubMed  CAS  Google Scholar 

  42. Cremerius U, Fabry U, Wildberger JE, et al. ­Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for ­non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2002;30:103–11.

    Article  PubMed  CAS  Google Scholar 

  43. Schot BW, Pruim J, van Imhoff GW, Sluiter WJ, Vaalburg W, Vellenga E. The role of serial pre-­transplantation positron emission tomography in ­predicting progressive disease in relapsed lymphoma. Haematologica. 2006;91:490–5.

    PubMed  Google Scholar 

  44. Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood. 2007;109:486–91.

    Article  PubMed  CAS  Google Scholar 

  45. Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011;117:7070–8.

    Article  PubMed  CAS  Google Scholar 

  46. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.

    Article  PubMed  CAS  Google Scholar 

  47. Bari A, Marcheselli L, Sacchi S, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol (Off J Eur Soc Med Oncol/ESMO). 2010;21:1486–91.

    Article  CAS  Google Scholar 

  48. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol (Off J Am Soc Clin Oncol). 2010;28:2373–80.

    Article  CAS  Google Scholar 

  49. Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–22.

    Article  PubMed  CAS  Google Scholar 

  50. Giachelia M, Voso MT, Tisi MC, et al. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-kB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2011;53(3):411–6.

    Article  PubMed  CAS  Google Scholar 

  51. Habermann TM, Wang SS, Maurer MJ, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood. 2008;112:2694–702.

    Article  PubMed  CAS  Google Scholar 

  52. Rossi D, Rasi S, Franceschetti S, et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leuk (Off J Leuk Soc Am Leuk Res Fund UK). 2009;23:1118–26.

    Article  CAS  Google Scholar 

  53. Kim DH, Jung HD, Kim JG, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006;108:2720–5.

    Article  PubMed  CAS  Google Scholar 

  54. Ahlgrimm M, Pfreundschuh M, Kreuz M, Regitz E, Preuss KD, Bittenbring J. Impact of Fc-gamma receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood. 2011;118(17):4657–62.

    Article  PubMed  CAS  Google Scholar 

  55. Oki Y, Yamamoto K, Kato H, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab. Eur J Haematol. 2008;81:448–53.

    Article  PubMed  Google Scholar 

  56. Plonquet A, Haioun C, Jais JP, et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2–3 diffuse large B-cell lymphoma. Ann Oncol (Off J Eur Soc Med Oncol/ESMO). 2007;18:1209–15.

    Article  CAS  Google Scholar 

  57. Wang F, Xu RH, Luo HY, et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer. 2008;8:115.

    Article  PubMed  Google Scholar 

  58. Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes de l’Adulte programs. J Clin Oncol (Off J Am Soc Clin Oncol). 2006;24:953–60.

    Article  Google Scholar 

  59. Morales D, Beltran B, De Mendoza FH, et al. Epstein-Barr virus as a prognostic factor in de novo nodal ­diffuse large B-cell lymphoma. Leuk Lymphoma. 2010;51:66–72.

    Article  PubMed  CAS  Google Scholar 

  60. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-­herpesviruses. Blood. 2009;113:1213–24.

    Article  PubMed  CAS  Google Scholar 

  61. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110:972–8.

    Article  PubMed  CAS  Google Scholar 

  62. Riihijarvi S, Koivula S, Nyman H, Rydstrom K, Jerkeman M, Leppa S. Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. Mod Pathol (Off J US Can Acad Pathol Inc). 2010;23:686–93.

    CAS  Google Scholar 

  63. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921–5.

    PubMed  CAS  Google Scholar 

  64. Fridberg M, Servin A, Anagnostaki L, et al. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk Lymphoma. 2007;48:2221–32.

    Article  PubMed  CAS  Google Scholar 

  65. Iqbal J, Meyer PN, Smith L, et al. BCL2 predicts survival in Germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res (Off J Am Assoc Cancer Res). 2011;17(24):7785–95.

    Article  CAS  Google Scholar 

  66. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res (Off J Am Assoc Cancer Res). 2009;15:5494–502.

    Article  CAS  Google Scholar 

  67. Meyer PN, Fu K, Greiner TC, et al. Immunohisto­chemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol (Off J Am Soc Clin Oncol). 2011;29:200–7.

    Article  Google Scholar 

  68. Young KH, Leroy K, Moller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008;112:3088–98.

    Article  PubMed  CAS  Google Scholar 

  69. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol (Off J Am Soc Clin Oncol). 2006;24:961–8.

    Article  CAS  Google Scholar 

  70. Lossos IS. Diffuse large B cell lymphoma: from gene expression profiling to prediction of outcome. Biol Blood Marrow Transplant (J Am Soc Blood Marrow Transplant). 2008;14:108–11.

    Article  CAS  Google Scholar 

  71. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105:13520–5.

    Article  PubMed  CAS  Google Scholar 

  72. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol (Off J Am Soc Clin Oncol). 2010;28:3360–5.

    Article  CAS  Google Scholar 

  73. Jardin F, Ruminy P, Kerckaert JP, et al. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas. Haematologica. 2008;93:543–50.

    Article  PubMed  CAS  Google Scholar 

  74. Jardin F, Jais JP, Molina TJ, et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood. 2010;116:1092–104.

    Article  PubMed  CAS  Google Scholar 

  75. Culpin RE, Proctor SJ, Angus B, Crosier S, Anderson JJ, Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. Int J Oncol. 2010;37:367–76.

    PubMed  CAS  Google Scholar 

  76. Lawrie CH, Soneji S, Marafioti T, et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer J Int Cancer. 2007;121:1156–61.

    Article  CAS  Google Scholar 

  77. Montes-Moreno S, Martinez N, Sanchez-Espiridion B, et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011;118:1034–40.

    Article  PubMed  CAS  Google Scholar 

  78. Alencar AJ, Malumbres R, Kozloski GA, et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res (Off J Am Assoc Cancer Res). 2011;17:4125–35.

    Article  CAS  Google Scholar 

  79. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417–29.

    Article  PubMed  CAS  Google Scholar 

  80. Rayman N, Lam KH, van der Holt B, et al. Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials. Clin Lymphoma Myeloma Leuk. 2011;11:23–32.

    Article  PubMed  Google Scholar 

  81. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.

    Article  PubMed  CAS  Google Scholar 

  82. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007;109:4930–5.

    Article  PubMed  CAS  Google Scholar 

  83. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol. 2006;208:714–23.

    Article  PubMed  CAS  Google Scholar 

  84. Natkunam Y, Farinha P, Hsi ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol (Off J Am Soc Clin Oncol). 2008;26:447–54.

    Article  CAS  Google Scholar 

  85. Lossos IS, Alizadeh AA, Rajapaksa R, Tibshirani R, Levy R. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood. 2003;101:433–40.

    Article  PubMed  CAS  Google Scholar 

  86. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828–37.

    Article  PubMed  CAS  Google Scholar 

  87. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100:9991–6.

    Article  PubMed  CAS  Google Scholar 

  88. Rimsza LM, Wright G, Schwartz M, et al. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. Clin Cancer Res (Off J Am Assoc Cancer Res). 2011;17:3727–32.

    Article  Google Scholar 

  89. Alizadeh AA, Gentles AJ, Alencar AJ, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood. 2011;118:1350–8.

    Article  PubMed  CAS  Google Scholar 

  90. Copie-Bergman C, Gaulard P, Leroy K, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol (Off J Am Soc Clin Oncol). 2009;27:5573–9.

    Article  Google Scholar 

  91. Meyer PN, Fu K, Greiner T, et al. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol. 2011;135:54–61.

    Article  PubMed  Google Scholar 

  92. Gratzinger D, Zhao S, Tibshirani RJ, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Investig (J Tech Methods Pathol). 2008;88:38–47.

    Article  CAS  Google Scholar 

  93. Evens AM, Sehn LH, Farinha P, et al. Hypoxia-inducible factor-1a expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol (Off J Am Soc Clin Oncol). 2010;28:1017–24.

    Article  CAS  Google Scholar 

  94. Sakata K, Satoh M, Someya M, et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer. 2004;100:356–65.

    Article  PubMed  CAS  Google Scholar 

  95. Wang L, Liu P, Chen X, Geng Q, Lu Y. Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. Med Oncol. 2011;29(3):2153–8.

    Article  PubMed  CAS  Google Scholar 

  96. Maurer MJ, Micallef IN, Cerhan JR, et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol (Off J Am Soc Clin Oncol). 2011;29:1620–6.

    Article  Google Scholar 

  97. Drake MT, Maurer MJ, Link BK, et al. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol (Off J Am Soc Clin Oncol). 2010;28:4191–8.

    Article  Google Scholar 

  98. Last KW, Cornelius V, Delves T, et al. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin’s lymphoma. J Clin Oncol (Off J Am Soc Clin Oncol). 2003;21:2335–41.

    Article  Google Scholar 

  99. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–5.

    Article  PubMed  Google Scholar 

  100. Lech-Maranda E, Bienvenu J, Michallet AS, et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw. 2006;17:60–6.

    PubMed  CAS  Google Scholar 

  101. Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol (Off J Am Soc Clin Oncol). 2005;23:2797–804.

    Article  Google Scholar 

  102. Niitsu N, Okamoto M, Okabe-Kado J, et al. Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin’s lymphoma. Leuk (Off J Leuk Soc Am Leuk Res Fund UK). 2001;15:832–9.

    Article  CAS  Google Scholar 

  103. Goto N, Tsurumi H, Kasahara S, et al. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. Eur J Haematol. 2011;87:217–27.

    Article  PubMed  CAS  Google Scholar 

  104. Bono P, Teerenhovi L, Joensuu H. Elevated serum ­endostatin is associated with poor outcome in patients with ­non-Hodgkin lymphoma. Cancer. 2003;97:2767–75.

    Article  PubMed  CAS  Google Scholar 

  105. Molina A. A decade of rituximab: improving ­survival outcomes in non-Hodgkin’s lymphoma. Annu Rev Med. 2008;59:237–50.

    Article  PubMed  CAS  Google Scholar 

  106. Armitage JO, Cheson BD. Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol. 1988;6:1335–47.

    PubMed  CAS  Google Scholar 

  107. A predictive model for aggressive non-Hodgkin’s lymphoma. The international Non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med. 1993;329:987–94.

    Google Scholar 

  108. Tilly H, Dreyling M. Diffuse large B-cell non-­Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5Suppl 5:v172–4.

    Article  PubMed  Google Scholar 

  109. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–6.

    Article  PubMed  CAS  Google Scholar 

  110. Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2007;25:787–92.

    Article  PubMed  CAS  Google Scholar 

  111. Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352:1197–205.

    Article  PubMed  CAS  Google Scholar 

  112. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–33.

    Article  PubMed  CAS  Google Scholar 

  113. Ketterer N, Coiffier B, Thieblemont C, et al. ACVBP versus ACVBP plus rituximab for young patients with localized low-risk diffuse large B-cell lymphoma. In: International conference on malignant lymphoma, Ann Oncol, Lugano; 2011. p. 91.

    Google Scholar 

  114. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol (Off J Am Soc Clin Oncol). 2008;26:2258–63.

    Article  CAS  Google Scholar 

  115. Recher C, Coiffier B, Haioun C, et al. Randomized phase 3 study (LNH03–2B) of intensified chemotherapy ACVBP plus rituximab versus standard CHOP plus rituximab for young patients with ­diffuse large B-cell lymphoma. 2011;378(9806):1858–67.

    Google Scholar 

  116. Gianni AM, Bregni M, Siena S, et al. High-dose ­chemotherapy and autologous bone marrow ­transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336:1290–7.

    Article  PubMed  CAS  Google Scholar 

  117. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the ­prospective LNH87–2 protocol—a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol. 2000;18:3025–30.

    PubMed  CAS  Google Scholar 

  118. Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:2796–802.

    PubMed  CAS  Google Scholar 

  119. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol. 2002;20:2472–9.

    Article  PubMed  CAS  Google Scholar 

  120. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287–95.

    Article  PubMed  CAS  Google Scholar 

  121. Greb A, Bohlius J, Trelle S, et al. High-dose chemotherapy with autologous stem cell support in ­first-line treatment of aggressive non-Hodgkin lymphoma—results of a comprehensive meta-analysis. Cancer Treat Rev. 2007;33:338–46.

    Article  PubMed  CAS  Google Scholar 

  122. Stiff PJ, Unger JM, Cook J, et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol. 2011;29. Abstract 8001.

    Google Scholar 

  123. Tarella C, Zanni M, Di Nicola M, et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia. 2007;21:1802–11.

    Article  PubMed  CAS  Google Scholar 

  124. Glass B, Ziepert M, Reiser M, et al. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol (Off J Eur Soc Med Oncol/ESMO). 2010;21:2255–61.

    Article  CAS  Google Scholar 

  125. Vitolo U, Chiappella A, Angelucci E, et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica. 2009;94:1250–8.

    Article  PubMed  CAS  Google Scholar 

  126. Fitoussi O, Belhadj K, Mounier N, et al. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica. 2011;96:1136–43.

    Article  PubMed  CAS  Google Scholar 

  127. Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). J Clin Oncol. 2012;13(12):1250–9.

    Google Scholar 

  128. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37–43.

    Article  PubMed  CAS  Google Scholar 

  129. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5.

    Article  PubMed  CAS  Google Scholar 

  130. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–7.

    Article  PubMed  CAS  Google Scholar 

  131. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284–9.

    Article  PubMed  CAS  Google Scholar 

  132. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634–41.

    Article  PubMed  CAS  Google Scholar 

  133. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.

    Article  PubMed  CAS  Google Scholar 

  134. Delarue R, Tilly H, Salles A, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03–6B GELA study. Blood. 2009;114. Abstract 406.

    Google Scholar 

  135. Cunningham D, Smith P, Mouncey P, et al. R-CHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol. 2011;29. Abstract 8000.

    Google Scholar 

  136. Ferreri AJ, Assanelli A, Crocchiolo R, Ciceri F. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematol Oncol. 2009;27:61–70.

    Article  PubMed  CAS  Google Scholar 

  137. Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516—the Southwest Oncology Group. J Clin Oncol. 2009;27:114–9.

    Article  PubMed  Google Scholar 

  138. Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol. 2011;12(13):1258–66.

    Article  PubMed  Google Scholar 

  139. Abramson JS, Hochberg EP. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116(18):4283–90.

    Article  PubMed  Google Scholar 

  140. Yamamoto W, Tomita N, Watanabe R, et al. Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol. 2010;85:6–10.

    PubMed  CAS  Google Scholar 

  141. Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol. 2011;90:809–18.

    Article  PubMed  CAS  Google Scholar 

  142. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5.

    Article  PubMed  CAS  Google Scholar 

  143. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117–22.

    PubMed  CAS  Google Scholar 

  144. Cabanillas F, Velasquez WS, McLaughlin P, et al. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin’s disease. Semin Hematol. 1988;25:47–50.

    PubMed  CAS  Google Scholar 

  145. Stamatoullas A, Fruchart C, Bastit D, et al. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Cancer. 1996;77:2302–7.

    Article  PubMed  CAS  Google Scholar 

  146. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3776–85.

    PubMed  CAS  Google Scholar 

  147. Gisselbrecht C, Mounier N. Rituximab: enhancing outcome of autologous stem cell transplantation in non-Hodgkin’s lymphoma. Semin Oncol. 2003;30:28–33.

    Article  PubMed  CAS  Google Scholar 

  148. Vellenga E, van Putten WL, van’t Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008;111:537–43.

    Article  PubMed  CAS  Google Scholar 

  149. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90.

    Article  PubMed  Google Scholar 

  150. Thieblemont C, Briere J, Mounier N, et al. The Germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29(31):4079–87.

    Article  PubMed  Google Scholar 

  151. Gisselbrecht C, Glass B, Laurent G, et al. Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. J Clin Oncol. 2011;29:8004.

    Google Scholar 

  152. El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose ­therapy. Ann Oncol (Off J Eur Soc Med Oncol/ESMO). 2007;18:1363–8.

    Article  CAS  Google Scholar 

  153. Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P, Pinto A. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin’s lymphoma: results of a pilot study. Ann Oncol (Off J Eur Soc Med Oncol/ESMO). 2006;17 Suppl 4Suppl 4:iv18–24.

    Article  Google Scholar 

  154. Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematol. 2008;143:607–21.

    Article  PubMed  CAS  Google Scholar 

  155. van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-­Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. 2011;29:1342–8.

    Article  PubMed  Google Scholar 

  156. Friedberg JW. New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. Clin Cancer Res (Off J Am Assoc Cancer Res). 2011;17:6112–7.

    Article  CAS  Google Scholar 

  157. Dunleavy K, Wilson WH. Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma. J Clin Oncol (Off J Am Soc Clin Oncol). 2010;28:e260. Author reply e1–2.

    Article  Google Scholar 

  158. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol (Off J Am Soc Clin Oncol). 2011;29:690–7.

    Article  CAS  Google Scholar 

  159. Furman RR, Martin P, Ruan J, et al. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 2010;116:5432–9.

    Article  PubMed  CAS  Google Scholar 

  160. Mozos A, Roue G, Lopez-Guillermo A, et al. The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large B-cell lymphoma. Am J Pathol. 2011;179(5):2601–10.

    Article  PubMed  CAS  Google Scholar 

  161. Hideshima T, Ikeda H, Chauhan D, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009;114:1046–52.

    Article  PubMed  CAS  Google Scholar 

  162. Dasmahapatra G, Lembersky D, Rahmani M, et al. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol Ther. 2009;8:808–19.

    Article  PubMed  CAS  Google Scholar 

  163. Dasmahapatra G, Lembersky D, Kramer L, et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood. 2010;115:4478–87.

    Article  PubMed  CAS  Google Scholar 

  164. Paoluzzi L, Gonen M, Bhagat G, et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood. 2008;112:2906–16.

    Article  PubMed  CAS  Google Scholar 

  165. Ferch U, Kloo B, Gewies A, et al. Inhibition of MALT1 protease activity is selectively toxic for ­activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2009;206:2313–20.

    Article  PubMed  CAS  Google Scholar 

  166. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large b-cell lymphoma in nongerminal center b-cell-like than in germinal center b-cell-like phenotype. Cancer. 2011;117(22):5058–66.

    Article  PubMed  CAS  Google Scholar 

  167. Leonard JP, Martin P, Barrientos J, Elstrom R. Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol. 2008;45:S11–6.

    Article  PubMed  CAS  Google Scholar 

  168. Witzig TE, Gupta M. Signal transduction inhibitor therapy for lymphoma. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program. 2010;2010:265–70.

    Article  Google Scholar 

  169. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578–85.

    Article  PubMed  CAS  Google Scholar 

  170. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107:13075–80.

    Article  PubMed  CAS  Google Scholar 

  171. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88–92.

    Article  PubMed  CAS  Google Scholar 

  172. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol (Off J Am Soc Clin Oncol). 2007;25:1741–6.

    Article  CAS  Google Scholar 

  173. Cerchietti LC, Ghetu AF, Zhu X, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 2010;17:400–11.

    Article  PubMed  CAS  Google Scholar 

  174. Briones J. Targeted therapy of BCL6-dependent diffuse large B-cell lymphomas by heat-shock protein 90 inhibition. Expert Rev Hematol. 2010;3:157–9.

    Article  PubMed  CAS  Google Scholar 

  175. Cerchietti LC, Hatzi K, Caldas-Lopes E, et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Investig. 2010;pii:42869.

    Google Scholar 

  176. Cerchietti LC, Lopes EC, Yang SN, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med. 2009;15:1369–76.

    Article  PubMed  CAS  Google Scholar 

  177. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol (Off J Am Soc Clin Oncol). 2008;26:2717–24.

    Article  CAS  Google Scholar 

  178. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319:1676–9.

    Article  PubMed  CAS  Google Scholar 

  179. Cardesa-Salzmann TM, Colomo L, Gutierrez G, et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica. 2011;96:996–1001.

    Article  PubMed  CAS  Google Scholar 

  180. Stopeck AT, Unger JM, Rimsza LM, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: southwest oncology group study S0108. Leuk Lymphoma. 2009;50:728–35.

    Article  PubMed  CAS  Google Scholar 

  181. Ganjoo KN, An CS, Robertson MJ, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma. 2006;47:998–1005.

    Article  PubMed  CAS  Google Scholar 

  182. Beltran BE, Castillo JJ, Morales D, et al. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol. 2011;86:663–7.

    Article  PubMed  Google Scholar 

  183. Castillo JJ, Beltran BE, Miranda RN, Paydas S, Winer ES, Butera JN. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist. 2011;16:87–96.

    Article  PubMed  Google Scholar 

  184. Hofscheier A, Ponciano A, Bonzheim I, et al. Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol (Off J US Can Acad Pathol Inc). 2011;24:1046–54.

    Google Scholar 

  185. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143:1144–50.

    Article  PubMed  Google Scholar 

  186. Petitjean B, Jardin F, Joly B, et al. Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype. Am J Surg Pathol. 2002;26:724–32.

    Article  PubMed  Google Scholar 

  187. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–32.

    Article  PubMed  CAS  Google Scholar 

  188. Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 2011;96(12):1888–90.

    Article  PubMed  CAS  Google Scholar 

  189. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12:460–8.

    Article  PubMed  CAS  Google Scholar 

  190. Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol (Off J Am Soc Clin Oncol). 2007;25:1916–23.

    Article  Google Scholar 

  191. Thieblemont C, Grossoeuvre A, Houot R, et al. Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol (Off J Eur Soc Med Oncol/ESMO). 2008;19:774–9.

    Article  CAS  Google Scholar 

  192. Advani RH, Chen H, Habermann TM, et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol. 2010;151:143–51.

    Article  PubMed  CAS  Google Scholar 

  193. Pfreundschuh M. How I, treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010;116:5103–10.

    Article  PubMed  CAS  Google Scholar 

  194. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. J Am Med Assoc. 2001;285:2750–6.

    Article  CAS  Google Scholar 

  195. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol (Off J Am Soc Clin Oncol). 2007;25:1824–31.

    Article  Google Scholar 

  196. Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993;342:1032–6.

    Article  PubMed  CAS  Google Scholar 

  197. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5:224–37.

    Article  PubMed  CAS  Google Scholar 

  198. Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer. 2009;115:4547–53.

    Article  PubMed  Google Scholar 

  199. Siegel AB, Lachs M, Coleman M, Leonard JP. Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures. Clin Lymphoma Myeloma. 2006;7:65–9.

    Article  PubMed  Google Scholar 

  200. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104:1998–2005.

    Article  PubMed  Google Scholar 

  201. Luciani A, Ascione G, Bertuzzi C, et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol (Off J Am Soc Clin Oncol). 2010;28:2046–50.

    Article  Google Scholar 

  202. Kobayashi Y, Miura K, Hojo A, et al. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2011;137:1079–84.

    Article  PubMed  Google Scholar 

  203. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol (Off J Am Soc Clin Oncol). 2011;29:3457–65.

    Article  CAS  Google Scholar 

  204. Janssen-Heijnen ML, Extermann M, Boler IE. Can first cycle CBCs predict older patients at very low risk of neutropenia during further chemotherapy? Crit Rev Oncol/Hematol. 2011;79:43–50.

    Article  Google Scholar 

  205. Hasselblom S, Stenson M, Werlenius O, et al. Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. Leuk Lymphoma. 2011;53(3):394–9.

    Article  PubMed  CAS  Google Scholar 

  206. Musolino A, Boggiani D, Panebianco M, et al. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated ­diffuse large B-cell non-Hodgkin lymphoma. Cancer. 2011;117:964–73.

    Article  PubMed  CAS  Google Scholar 

  207. Meguro A, Ozaki K, Sato K, et al. Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leuk Lymphoma. 2011;53(1):43–9.

    Article  PubMed  CAS  Google Scholar 

  208. Visani G, Ferrara F, Alesiani F, et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lymphoma. 2008;49:1081–6.

    Article  PubMed  CAS  Google Scholar 

  209. Corazzelli G, Frigeri F, Arcamone M, et al. Biweekly rituximab, cyclophosphamide, vincristine, non-­pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy. Br J Haematol. 2011;154:579–89.

    Article  PubMed  CAS  Google Scholar 

  210. Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011;11(6):462–6.

    Article  PubMed  CAS  Google Scholar 

  211. Weidmann E, Neumann A, Fauth F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol (Off J Eur Soc Med Oncol/ESMO). 2011;22:1839–44.

    Article  CAS  Google Scholar 

  212. Rigacci L, Fabbri A, Puccini B, et al. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)+/−rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. Cancer. 2010;116:4573–9.

    Article  PubMed  CAS  Google Scholar 

  213. Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica. 2008;93:1837–42.

    Article  PubMed  Google Scholar 

  214. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.

    Article  PubMed  CAS  Google Scholar 

  215. Zwick C, Hartmann F, Zeynalova S, et al. Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol (Off J Eur Soc Med Oncol/ESMO). 2011;22:1872–7.

    Article  CAS  Google Scholar 

  216. Brunello A, Kapoor R, Extermann M. Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. Am J Clin Oncol. 2011;34:292–6.

    Article  PubMed  CAS  Google Scholar 

  217. Lin PC, Hsiao LT, Poh SB, et al. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP. Ann Hematol. 2007;86:95–100.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and UMR918, Centre Henri Becquerel, Université de Rouen, Rouen, 76000, France

    Fabrice Jardin MD, PhD & Hervé Tilly MD

Authors
  1. Fabrice Jardin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hervé Tilly MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hervé Tilly MD .

Editor information

Editors and Affiliations

  1. Holcombe Blvd. 1515, Houston, 77030, Texas, USA

    Anas Younes

  2. Service d'Hematologie, CHU Lyon-Sud, chemin du Grand Revoyet, Pierre Bénite, 69310, France

    Bertrand Coiffier

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Jardin, F., Tilly, H. (2013). Diffuse Large B-Cell Lymphoma. In: Younes, A., Coiffier, B. (eds) Lymphoma. Current Clinical Oncology, vol 43. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-408-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-408-1_11

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-407-4

  • Online ISBN: 978-1-62703-408-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation